StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
Shares of Bellerophon Therapeutics stock opened at $0.01 on Thursday. The stock’s 50-day moving average is $0.03 and its 200 day moving average is $0.04. Bellerophon Therapeutics has a one year low of $0.01 and a one year high of $0.02. The firm has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74.
Bellerophon Therapeutics Dividend Announcement
The firm also recently declared a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were paid a dividend of $0.019 per share. The ex-dividend date was Thursday, December 19th. This represents a yield of 117.8%.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Top 3 Investment Themes to Watch for in 2025
- How to Capture the Benefits of Dividend Increases
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- Comparing and Trading High PE Ratio Stocks
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
